1 / 1

palbociclib(Ibrance)

Acetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine Injection

Reference price:

Manufacturer:

Pfizer Inc.

Formulation:

CAPSULE

Validity period:

24 months

Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.

Ibrance(palbociclib) Instructions:Uses,Dosage, Side Effects

IBRANCE (palbociclib) is an orally administered kinase inhibitor formulated as capsules. It functions by selectively inhibiting cyclin-dependent kinases 4 and 6 (CDK4/6), which are key regulators of cell cycle progression.

It is indicated for use in combination with specific endocrine therapies for the treatment of advanced breast cancer. The product is supplied in three dosage strengths.

Generic name

palbociclib(Ibrance)

English name

palbociclib

Alternative Names

Ibrance

Drug prices

Indications

In combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women or men.

In combination with fulvestrant in patients with disease progression following endocrine therapy.

In combination with inavolisib and fulvestrant for the treatment of endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative locally advanced or metastatic breast cancer.

Therapeutic Target

Cyclin-dependent kinases 4 and 6 (CDK4/6)

Active Ingredients

Palbociclib

Dosage form

CAPSULE

specifications

125mg*21 capsules/box

Description

Dosage and Administration

Recommended starting dose: 125 mg orally once daily with food for 21 days, followed by 7 days off.

Dose adjustments may be required based on hematologic and non-hematologic toxicities.

Avoid concomitant use with strong CYP3A inhibitors or inducers.

For patients with severe hepatic impairment (Child-Pugh Class C), the recommended dose is 75 mg once daily.

CATEGORY NAVIGATION